Ziyou Lin
Overview
Explore the profile of Ziyou Lin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
874
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dong C, Lin Z, Hu Y, Lu Q
J Cancer
. 2025 Jan;
16(3):982-995.
PMID: 39781341
Killer Cell Lectin Like Receptor D1 (KLRD1) plays a crucial role in antitumor immunity. However, its expression patterns across various cancers, its relationship with patient prognosis, and its potential as...
2.
Jing T, Zhang Z, Kang Z, Mo J, Yue X, Lin Z, et al.
J Med Chem
. 2023 May;
66(10):6811-6835.
PMID: 37159395
A series of novel compounds bearing a cyclopropyl linkage were designed, synthesized, and evaluated as programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors. An optimized compound (1,2)- showed potent...
3.
Lu J, Li J, Lin Z, Li H, Lou L, Ding W, et al.
Cancer Lett
. 2023 May;
564:216205.
PMID: 37146936
Cross-talk between the tumor microenvironment (TME) and cancer cells plays an important role in acquired drug resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). The role of tumor-associated...
4.
Lin Z, Li J, Zhang J, Feng W, Lu J, Ma X, et al.
Cancer Res
. 2023 Apr;
83(13):2187-2207.
PMID: 37061993
Significance: IGF2BP3 stabilizes COX6B2 to increase oxidative phosphorylation and to drive resistance to EGFR inhibitors in lung cancer, which provides a therapeutic strategy to overcome acquired resistance by targeting metabolic...
5.
Mo J, Deng L, Peng K, Ouyang S, Ding W, Lou L, et al.
J Hematol Oncol
. 2023 Feb;
16(1):15.
PMID: 36849939
The acute myeloid leukemia (AML) patients obtain limited benefits from current immune checkpoint blockades (ICBs), although immunotherapy have achieved encouraging success in numerous cancers. Here, we found that V-domain Ig...
6.
Lin Z, Wan A, Sun L, Liang H, Niu Y, Deng Y, et al.
Mol Ther
. 2022 Oct;
31(2):517-534.
PMID: 36307991
N6-methyladenosine (mA) is the most pervasive RNA modification and is recognized as a novel epigenetic regulation in RNA metabolism. Although the mA modification involves various physiological processes, its roles in...
7.
Ouyang S, Li H, Lou L, Huang Q, Zhang Z, Mo J, et al.
Redox Biol
. 2022 Apr;
52:102317.
PMID: 35483272
Chemotherapy is still one of the principal treatments for gastric cancer, but the clinical application of 5-FU is limited by drug resistance. Here, we demonstrate that ferroptosis triggered by STAT3...
8.
Niu Y, Lin Z, Wan A, Sun L, Yan S, Liang H, et al.
Hepatology
. 2021 Apr;
74(3):1461-1479.
PMID: 33813748
Background And Aims: Hypoxia is a common feature of the tumor microenvironment (TME), which promotes tumor progression, metastasis, and therapeutic drug resistance through a myriad of cell activities in tumor...
9.
Sun L, Wan A, Zhou Z, Chen D, Liang H, Liu C, et al.
Gut
. 2020 Nov;
70(9):1698-1712.
PMID: 33219048
Objective: Dysregulated cellular metabolism is a distinct hallmark of human colorectal cancer (CRC). However, metabolic programme rewiring during tumour progression has yet to be fully understood. Design: We analysed altered...
10.
Lin Z, Niu Y, Wan A, Chen D, Liang H, Chen X, et al.
EMBO J
. 2020 May;
39(12):e103181.
PMID: 32368828
N6-methyladenosine (m A) is an abundant nucleotide modification in mRNA, known to regulate mRNA stability, splicing, and translation, but it is unclear whether it is also has a physiological role...